Machine-learning-assisted continuous flow synthesis of clonidine

Clonidine•HCl is a clinically important imidazoline derivative whose manufacturing routes have seen little innovation since their development in the mid-to-late 20th century. Its widespread use as an antihypertensive and neuroactive agent underscores the need for more efficient, modern production strategies. Herein, we report the first continuous flow strategy for the synthesis of clonidine. By integrating telescoped multistep sequences, inline liquid-liquid workup, advanced solid handling, and machine learning, we developed an intensified process that delivers clonidine•HCl in only 24 min total residence time across 5 continuous transformations, achieving an overall yield of 54%. This approach significantly outperforms conventional batch protocols, which typically require more than 18 h. The platform enables efficient and precisely controlled isothiocyanate formation, thiourea hydrolysis, S-methylation, and imidazoline cyclisation, while reducing intermediate isolations, minimising reagent handling, and eliminating hazardous materials associated with legacy routes. These advances provide a scalable, data-driven manufacturing solution and establish a foundation for intensified production of clonidine and related APIs under continuous flow conditions. Despite the long-established clinical importance of clonidine, its synthesis still relies on conventional batch processing, hazardous reagents, and inherently long reaction times. Here, the authors present a machine learning-optimised continuous flow strategy that delivers clonidine in just 24 min across five transformations, achieving a 54% overall yield and significantly outperforming traditional protocols requiring over 18h.